Objective: The aim of this study is to clarify the value of the aetiological diagnosis of mutation in thrombophilic genes gene, prothrombin gene and methylenetetrahydrofolate reductase gene in women with repeated IVF-embryo transfer failure with unknown causes.
Introduction

IN-VITRO Fertilization and embryo transfer (IVF-
) is only one method of assisted reproduction that enables couples to turn their dream of having a child into a reality. However, about Two-thirds of couples fail to achieve an ongoing pregnancy due to repeated implantation failure. Repeated implantation failure (RIF) is defined as failure to achieve a pregnancy following 2-6 in vitro fertilization (IVF) cycles, in which embryos were transferred to the uterus [1] . Failure could be caused by many different factors such as reduced endometrial receptivity, embryonic defects or multifactorial causes [2] . Thrombophilias, either acquired or hereditary, may shift the hemostatic balance towards enhanced coagulation [3] . Inherited factors for thrombophilia include mutation in factor V Leiden, prothrombin and methylenetetrahydrofolate reductase (MTHFR) genes which are major causes of thromboembolic diseases. Moreover, it may predispose for pregnancy complications with different mechanisms [4] .
Factor V (FV) Leiden mutation is the most common hereditary thrombophilia [5] . This mutation slows down the proteolytic degradation of factor Va by activated protein C leading to increased generation of thrombin [6] . The mutation of prothrombin gene leads to significantly elevated plasma prothrombin level that increases the risk of venous thromboembolism 3-fold [7] . The mutation in MTHFR gene leads to a reduction in the activity of this enzyme [8] , results in decreased synthesis of 5-methyltetrahydrofolate, the primary methyl donor in the conversion of homocysteine to methionine, and the resulting increase in plasma homocysteine concentrations which is a risk factor for venous and arterial thrombosis [9] .
Acquired thrombophilia is associated with thrombophilic factors with no inherited characteristics, such as anticardiolipin antibody (ACA) and lupus anticoagulant (LA), the detection of antiphospholipid antibodies (APA) such as ACA and LA seems to be higher in the first trimester in women who have antiphospholipid syndrome (APS) [10] . The known thrombotic nature of the placental lesions and the risk associated with both acquired and genetic thrombophilias strongly suggest a cause-effect relationship between thrombophilias and severe obstetric complications. The evidence of thrombosis or infarcts in the placental sections suggests a haemostatic abnormality with thrombophilia [11] . Placental thrombosis may be final com-mon pathophysiologic pathway in most women with habitus abortions and repeated pregnancy wastage [12] . Thrombophilia has a significant role in IVF-embryo transfer implantation failure [13] . The aim of this study is to clarify the value of the aetiological diagnosis of mutation in thrombophilic genes [factor V (FV) gene, prothrombin (PT) gene and methylenetetrahydrofolate reductase (MTHFR) gene] in women with repeated IVF-embryo transfer failure with unknown causes.
Material and Methods
This comparative cross-sectional observational study was performed on 60 women divided into two Control groups (group A & B) and one patient group described as follow. Group A included 20 consecutive women who conceived spontaneously with no previous history of miscarriage, treated at the IVF Unit of the Benha university hospital between January 2009 and June 2009. Group B Included 20 women who have had successful pregnancy after their first IVF-embryo transfer cycle. Study group included 20 women with two or more previously failed IVF-embryo transfer cycles with unknown causes and they were matched to the CONTROL patients with regard to age. The study was approved by the institutional ethics committee, and all subjects signed an informed consent form. Women with endometriosis, hydrosalpinx, abnormal uterine cavity on the hysterosalpingogram and history of thromboembolic disease, and those receiving hormonal treatment were excluded. All women were investigated for the Detection of Genotype mutation of the three thrombophillic genes (FVL mutation G1691A, prothrombin mutation (PTH) G20210A and MTHFR C677T)
DNA extraction and PCR assay:
Genomic DNA was extracted from whole-blood samples. The genotypes of prothrombin (G2021 0A), FV (G1691A) and MTHFR (C677T) were determined by using the HVD StripAssay kit manufactred by "Viennalab. Diagnostika GmbH". Multiplex PCR amplification reaction mixture was prepared for each sample using biotinylated primers with specific sequences for detections of different genotype mutations in the three genes (FVL-PTH and MTHFR). In a G-storm themocycler (United kingdom) the PCR program was depicted in Table (5) . The amplified DNA was analyzed by gel electrophoresis. 10µ l of each reaction mixture and 1000 bp ladder (molecular weight marker) was separated on 3% agarose gel contain 0.3 µ g/ml of ethidium bromide. The bands of fragment lengths suspected to see at 173, 202, 223bp indicate successful amplification. the amplified products were selectively hybridized to strip Assay which was containing allelespecific oligonucleotide probes (wild and mutant specific) immobilized as an array of parallel lines, was used instead of using radioactive probe, the bound biotinylated sequences were detected using streptavidin-alkaline phosphatase and color substrates. In a thermoshaker (Shy line shaker DTS-2) 10µ l of each amplification product was used in the typing trays with 1ml Hybridization Buffer added to Teststrip with orbital shaking at 45ºC for 30min. at 50 rpm Washing performed at 45ºC with shaking.
For each test strip, 1ml Conjugate Soultion (contains streptavidin-alkaline phosphatase) was added and incubated for 15min. at room temperature. After that 1ml Color Developer (contains nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate) was added and Incubated for 15min. at room temperature in the dark on orbital shaker. The genotype and allelic mutation were determined as follow. Results were presented as means ± SD, comparisons of categorical variables were made between patient and control groups using chi-square test, the sperman's correlation coefficient was used to measure the closeness of a linear relationship between the results of mutation in thrombophilic genes and the frequency of repeated IVF-embryo transfer cycle. The statistics package for social sciences (SPSS) and Microsoft Office Excel were used for data processing and data analysis. Differences were considered as statistically significant for a p-value less than 0.05.
Results
The mean age in groups A, B and study groups were 29.0±4.87, 28.1 ± 5.04 and 33.2 ± 6.52 respectively. There was statistically significant increase in the maternal age of patients in study group, as compared to control groups, however, there is no statistically significant increase in body mass index (BMI) of patients, as compared to control groups, (p>0.05) ( Table 1 ).
There was high statistically significant increase in percentage of allele frequency and number of patients with factor V, prothrombin and methylenetetrahydrofolate reductase genes mutations in the study group as compared to control groups (p<0.001). There are high statistically significant increase in the number of patients with single and multiple genes mutation (two or more), as compared to control groups (p<0.001). There is no statistically significant correlation between maternal age and number of IVF among In Vitro Fertilization (IVF) failed patients and IVF Successful controls. There is no statistically significant increase in maternal age and number of In Vitro Fertilization (IVF) failed patients with single and multiple genes mutation, as compared to In Vitro Fertilization (IVF) failed patients with normal genes (p>0.05) (Tables 2-4) 
Discussion
Our study showed that the allele frequency of factor V Leiden (FVL) in our control groups is (5%) which was similar with the (4.3%) reported for the population of Greece [14] . Our data showed significant increase of allele frequency as well as homozygosity and heterozygosity of FVL gene in women with repeated IVF-embryo transfer failure as compared to control groups. Our data were in agreement with Foka, et al., 2000 [14] who documented an association between factor V Leiden and fetal loss after IVF and demonstrated a 4-fold, 2.2-fold and 4-fold increase correspondingly in the prevalence of factor V Leiden in women with fetal loss after IVF as compared to controls
The most frequent reasons of thrombophilia are the following: Factor V Leiden (1691G>A), mutation 20210G>A of prothrombin gene, and 677C>T of 5, 10-methylenetetrahydrofolate reductase gene [15] . Inherited or acquired thrombophilia have been recently implicated in early pregnancy loss and IVF implantation failure, by impairing the initial vascularization process occurring at implantation, which is necessary for a successful pregnancy [16] .
In FVL, arginine is substituted by glutamine at amino acid residue 506 in coagulation factor V [17] . Due to this substitution, factor Va becomes resistant to degradation by activated protein C, increasing the risk of venous thromboembolism 3-5 fold in heterozygous individuals [18] . The current findings were in agreement with those of Grandone, et al., 2001 , who reported an association between IVF-embryo transfer failure and an increased incidence of thrombophilia [19] In addition, it has been shown that the prevalence of FVL mutation was higher in women with repeated IVF failure than was found in women with successful IVF-embryo transfer and the healthy controls [13] . Moreover, Rey, et al., 2003 reported that 3-to 4 fold increased risk of recurrent early pregnancy loss was found in women with FVL mutation [20] .
Mutation in FVL gene increases thrombin generation, with a 4-to 8 fold increased risk of thrombosis in the heterozygous mutation and 80-fold increased risk in the homozygous mutation [16] and a high prevalence of thrombophilia in women with repeated IVF-embryo transfer failure as compared with normal women [21] .
Recently, it has been observed significant associations with early and late pregnancy loss and carriers of the heterozygous factor V Leiden mutation [22] . On the other hand, it has been suggested that that factor V Leiden is not a predisposing factor for recurrent fetal loss after IVF [23] which disagree with our findings. Furthermore, it has been shown higher intracytoplasmic sperm injection (ICSI) success in mother-child pairs with a factor V Leiden, Suggesting that a thrombotic tendency of carriers of the Leiden mutation has some advantage in fetal implantation [24] .
Our finding may be explained by Grandone, et al., who reported an association between hereditary thrombophilias and increased complications of pregnancy, such as severe preeclampsia, fetal growth restriction, and stillbirth and abruptio placenta [19] . Also, Kupferminc, et al., suggested that thrombosis of maternal vessels and reduced perfusion to the intervillous space may contribute to these complications in association with thrombophilias [25] . Moreover, it has been suggested that invasion of maternal vessels by the syncythiotrobopblast may be affected by local microthrombosis at the site of implantation loading to implantation failure or pregnancy loss/miscarriage [21] .
Prothrombin is the precursor molecules of thrombin, which activates factor V and VIII and converts fibrinogen to fibrin (Murin, et al., 1998) . The G20210A variant in the 3' untranslated region (UTR) of prothrombin gene (FII G20201A) is associated with higher plasma prothrombin activity and has a prevalence of 1.2-4.6% in the general Caucasian population [26] . In the case of prothrombin (PTH), our study showed significant increase of allele frequency as well as homozygosity and heterozygosity of PTH gene mutation in women with repeated IVF-embryo transfer failure as compared to control groups.
Our results were in agreement with Foka, et al., who reported that prothrombin G20210A was significantly more common in women with fetal loss after IVF than in controls [14] . Also, Grandone, et al., reported that an association between thrombophilia due to prothrombin mutation and IVF implantation failure [27] . Recently, Lindohff-Last and Luxembourg, observed significant associations with early and late pregnancy loss and carriers of the heterozygous prothrombin-mutation G20210A [22] . In the same year, Di Micco, et al., supported that the homozygosis for the FII G20210A variant may be a risk factor also for arterial thrombotic events besides of venous thromboembolism [26] . On the other hand Ktitteh, et al., did not find any association between prothrombin G20210A polymorphism and fetal losses after IVF [28] . Our finding may be explained by Kujovich, who reported that elevated plasma prothrombin levels with 2-to 4 fold increased risk of venous thrombosis were found in association with a single-nucleotide substitution (G20210A) in the 3' untranslated regions of the prothrombin gene [16] .
Moreover, Rey, et al., reported that mutation in prothrombin gene was associated with a 2-to 3-fold increased risk repeated IVF-embryo transfer failure [20] . The homozygous state for the C to T transition at position 677 of MTHFR gene is associated with hyperhomocysteinaemia which predisposes to thrombosis [29] . In the study of MTHFR, our results showed significant increase of allele frequency as well as homozygosity and heterozy-gosity of MTHFR gene mutation in women with repeated IVF-embryo transfer failure as compared to control groups.
Our finding were consistent with Unfried, et al., who reported that homozygosity for a common C677T mutation in the 5,10-MTHER gene that was associated with hyperhomocystinaemia leads to a 3-fold increase in risk for early miscarriages [30] . In addition, Engbersen, et al., 1995 reported that homozygosity for the thermolabile variant of MTHFR predisposes to the development of hyperhomocystinaemia [31] . Also, Nelen, et al., evaluated the relationship between recurrent early pregnancy loss and hyperhomocysteinaemia and the MTHFR C677T mutation [32] . Recently, Mukhopadhyay, et al., finding supported the association between MTHFR C677T and patients with early recurrent pregnancy loss (RRL) [33] . Our results were controversial the results of, Rey, et al., who suggested that MTHFR may not be important in recurrent miscarriage [20] .
Our data supported by Heby, who reported that elevated maternal plasma homocystine levels were associated with impaired DNA methylation and gene expression that lead to defective chorionic villous vascularization with subsequent early embryonic death. In the case of multiple genes mutation, our results showed significantly increased prevalence of multiple thrombophilic genes mutation (of FV, PTH and MTHFR) in women with repeated IVF-embryo transfer failure as compared to control groups [34] .
Our findings were in agreement with those reported by Colman, et al., who observed that women with recurrent implantation failure after IVF-embryo transfer had three or more gene mutations compared with healthy fertile controls [35] Also, Azem, et al., showed that at least one thrombophilic factor was detected in women who have had previously two or more IVF-embryo transfer failures [21] . In addition, Grandone, et al., 2001 reported that mutations of the factor V Leiden and prothrombin genes might play a role in implantation failure or in fetal loss after IVF [19] .
Recently, Di Micco, et al., reported that inherited thrombophilia and in particular the prothrombin A20210G variant is relevant risk factor for recurrent pregnancy loss [26] . There were many possible explanations for our finding. First, all patients in our study were of the same ethnic origin. Differences in the prevalence of thrombotic mutations according to ethnicity are likely to result in various strengths of associations in different populations.
Second, strict criteria for selecting patients in our study were applied. All women were apparently healthy with no previous history of thyroid disease, diabetes mellitus or thromboembolic disease [13] . Furthermore, women with endometriosis, hydrosalpinx, abnormal uterine cavity on the hysterosalpingogram and history of thromboembolic disease and those who were receiving hormonal treatment were not included in the study group and only cycles in which grade 1 and 2 embryos were included. Such a selection may be responsible for the increased prevalence of thrombophilia in our study [13] .
Finally, we conclude that factor V, prothrombin and methylenetetrahydrofolate reductase gene mutation may have a significant role in repeated implantation failure following IVF/ICSI treatment cycles.
